|
| Retrospective study of Jinghua Weikang Capsule combined with bifidobacterium in treating Helicobacter pylori infection |
| Hits 848 Download times 477 Received:October 16, 2021 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2022.01.07 |
| Key Words
Jinghua Weikang Capsule;bifidobacterium;helicobacter pylori;eradication rate;adverse reaction |
| Author Name | Affiliation | E-mail | | WANG Qiuming | Department of Digestive Internal Medicine, Beijing Hospital of Traditional Chinese Medicine Attached to Capital Medical University, Beijing 100010, China | | | ZHOU Qiang | Department of Digestive Internal Medicine, Beijing Hospital of Traditional Chinese Medicine Attached to Capital Medical University, Beijing 100010, China | | | HU Jing | Centre for Evidence-Based Medicine, Beijing Institute of Traditional Chinese Medicine, Beijing 100010, China | | | DING Yang | Department of Digestive Internal Medicine, Beijing Hospital of Traditional Chinese Medicine Attached to Capital Medical University, Beijing 100010, China | | | ZHANG Shengsheng | Department of Digestive Internal Medicine, Beijing Hospital of Traditional Chinese Medicine Attached to Capital Medical University, Beijing 100010, China | zhangshengsheng@bjzhongyi.com |
|
| Abstract
|
| [Objective] To evaluate the therapeutic effect of Jinghua Weikang Capsule combined with bifidobacterium on patients with helicobacter pylori （Hp） infection and identified with the dampness-heat syndrome in the spleen and stomach. [Methods] This study was a retrospective research based on a total of 115 patients who were admitted to The Digestion Center of Beijing Hospital of Traditional Chinese Medicine Attached to Capital Medical University，with Hp infection and identified with the dampness-heat syndrome in the spleen and stomach. Via different treatment methods，the patients were divided into three groups：quadruple therapy group（35 cases），Jinghua Weikang Capsule combined with quadruple therapy group （42 cases） and Jinghua Weikang Capsule combined with bifidobacterium therapy group （38 cases）. All cases were evaluated by 13C or 14C-urea breath test （UBT） after being treated for 14 days，with over 4 weeks long drug withdrawal. The single symptom frequency，therapeutic evaluation of clinical symptoms，eradication rate of helicobacter pylori and occurrence of adverse reactions were observed and assessed. [Results] For patients infected with Hp，the single symptom frequency was epigastric distention，epigastric pain and ozostomia in sequence. There was no significant statistical difference （P>0.05） in Hp eradication rate between the quadruple therapy group （80.00%） and the Jinghua Weikang Capsule combined with bifidobacterium therapy group （68.42%）. Hp eradication rate of Jinghua Weikang Capsule combined with quadruple therapy group （92.86%） was higher than that of Jinghua Weikang Capsule combined with bifidobacterium therapy group，with the significant statistical difference （P<0.01）；meanwhile，its Hp eradication rate was higher than that of quadruple therapy group，with no statistical difference （P>0.05）. As for the therapeutic evaluation of clinical symptoms and adverse reactions，the Jinghua Weikang Capsule combined with bifidobacterium therapy group was obviously superior to the other two groups，with the significant statistical difference （P<0.05）. [Conclusion] The therapy of Jinghua Weikang Capsule combined with bifidobacterium，characterized by highly complied and less adverse reactions，can eradicate Hp and is effective in improving clinical symptoms. |
|
|
|
|
|
|
|
